HeartBeam (BEAT) Telefonkonferenz zu den Ergebnissen des 2. Quartals 2026: FDA-Einreichung, geringerer Cash-Burn und kommerzielle Markteinführung
Die Telefonkonferenz von HeartBeam zu den Ergebnissen des zweiten Quartals 2026 behandelte einen Nettoverlust von 5 Millionen US-Dollar, einen geringeren Cash Burn, Fortschritte bei der FDA sowie die frühe kommerzielle Markteinführung in vier US-Märkten.
HeartBeam, Inc. is a cardiac technology company. The Company focuses on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. It is engaged in the development of higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented electrocardiography technology platform. It is developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It is developing its own product, the HeartBeam System. The HeartBeam System comprises a credit card sized 12-lead output electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. The core technology consists of a series of patented inventions that allow it to capture the heart’s electrical activity from three distinct directions.
SektorMedizinische Geräte und Verbrauchsmaterialien